Optimizing quality of life in multiple myeloma patients: current options, challenges and recommendations

References

• Palumbo A, Anderson K. Multiple myeloma. N Engl J med 2011;364:1046-60
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20
   PubMed Web of Science ®Google Scholar
• Turesson I, Velez R, Kristinsson SY, et al. Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic. Mayo Clin Proc 2010;85:225-30
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Landgren O, Dickman PW, et al. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007;25:1993-9
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dispnezieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014;28:1122-8
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Ludwig H, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 2011;118(17):4519-27
   PubMed Web of Science ®Google Scholar
• Zweegman S, Palumbo A, Bringhen S, et al. Age and aging in blood disorders: multiple myeloma. Haematologica 2014;99(7):1133-7
   PubMed Web of Science ®Google Scholar
• Osborne T, Ramsenthaler C, Siegert R, et al. What issues matter most to people with multiple myeloma and how well are we measuring them? A systematic review of quality of life tools. Eur J Haematol 2012;89:437-57
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30:a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76
   PubMed Web of Science ®Google Scholar
• Cocks K, Cohen D, Wisloff F, et al. An international field study of the reliability and validity of a disease specific questionnaire module (the QLQ-MY20) in assessing qualityof life of patients with multiple myeloma. Eur J Cancer 2007;43:1670-8
   PubMed Web of Science ®Google Scholar
• Espinoza-Zamora J, Portilla-Espinosa CM, Labardini-Méndez JR, et al. Quality of life in multiple myeloma: clinical validation of the Mexican-Spanish version of the QLQ-MY20 instrument. Ann Hematol 2015. [Epub ahead of print]
   Google Scholar
• Proskorovsky I, Lewis P, Wiliams C, et al. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma. Health Qual Life Outcomes 2014;35:1-9
   Google Scholar
• Sonneveld P, Verelst SG, Lewis P, et al. Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia 2013;27:1959-69
   PubMed Web of Science ®Google Scholar
• Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012;119:4375-82
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Flinn IW, Rifkin R, et al. Efficacy and safety of three bortezomib-based combinations in elderly, newly diagnosed multiple myeloma patients: results from all randomized patients in the community-based, phase 3 UPFRONT study. ASH Annual Meeting Abstracts 2011;118(2):478
   Google Scholar
• Morgan GJ, Davies FE, Gregory WM, et al. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood 2011;118(5):1231-8
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar V, San Miguel JF, et al. International Myeloma Working Group Consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol 2014;6(32):587-600
   Google Scholar
• Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012;366(19):1759-69
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Jacob S, Calendar NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasonse as initial therapy for newly diagnosed multiple myeloma: an open-label randomized controlled trial. Lancet Oncol 2010;11(1):29-37
   PubMed Web of Science ®Google Scholar
• Wijermans P, Schaafsma M, Termorshuizen F, et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the Hovon 49 study. J Clin Oncol 2010;28:3160-6
   PubMed Web of Science ®Google Scholar
• Verelst SG, Termorshuizen F, Uyl-de Groot CA, et al. Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial. Ann Hematol 2011;90:1427-39
   PubMed Web of Science ®Google Scholar
• Waage A, Gimsing P, Fayers P, et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 2010;116:1405-12
   PubMed Web of Science ®Google Scholar
• Delforge M, Dhawan R, RobinsonJr, et al. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP versus MP: results from the VISTA trial. Eur J Haematol 2012;89:16-27
   PubMed Web of Science ®Google Scholar
• Dhawan R, Meunier J, Regnault A, et al. Impact of complete response on health-related quality of life in newly diagnosed multiple myeloma patients: results from the VISTA trial. XII International Myeloma Workshop (IMW), Washington DC; USA. Clin Lymphoma Myeloma 2009;9:S58; Abstract 352
   Google Scholar
• Niesvizky R, Flinn IW, Rifkin R, et al. Patient-reported quality of life (QoL) in elderly, newly diagnosed multiple myeloma (MM) patients receiving bortezomib-based combinations: results from all randomized patients in the community-based, phase 3b UPFRONT study. Proceedings of the 53rd Annual Meeting of the American Society of Hematology (ASH), San Diego, CA, USA. Blood 2011;118:Abstract 1864
   Google Scholar
• Dimopoulos MA, Delforge M, Hajek R, et al. Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. Haematologica 2013;98:784-8
   PubMed Web of Science ®Google Scholar
• Delforge M, Minuk L, Eisenmann JC, et al. Health-related quality of life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone vs. melphalan-prednisone-thalidomide. J Clin Oncol 2014;32:abstr 8516
   Google Scholar
• Dubois D, Dhawan R, van de Velde H, et al. Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. J Clin Oncol 2006;24:976-82
   PubMed Web of Science ®Google Scholar
• Lee SJ, Richardson PG, Sonneveld P, et al. Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br J Haematol 2008;143:511-19
   PubMed Web of Science ®Google Scholar
• Hjorth M, Hjertner O, Knudsen LM, et al. Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. Eur J Haematol 2012;88:485-96
   PubMed Web of Science ®Google Scholar
• Alegre A, Oriol-Rocafiguera A, Garcia-Larana J, et al. Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience. Leuk Lymphoma 2012;53:1714-21
   PubMed Web of Science ®Google Scholar
• Song KW, Dimoupoulos MA, Weisel KC, et al. Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma. Haematologica 2015;100(2):e63-7
   PubMedGoogle Scholar
• Osborne T, Ramsenthaler C, de Wolf-Linder S, et al. Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life. BMC Cancer 2014;14:496
   PubMed Web of Science ®Google Scholar
• Kvam AK, Wisloff F, Fayers PM. Minimal important differences and response shift in health-related quality of life; a longitudinal study in patients with multiple myeloma. Health Qual Life Outcomes 2010;8:79
   Google Scholar
• van der Poel M, Oerlemans S, Schouten HC, et al. Elderly multiple myeloma patients experience less deterioration in health-related quality of life than younger patients compared to a normative population: a study from the population-based PROFILES registry. Ann Hematol 2014. [Epub ahead of print]
   Google Scholar
• Jordan K, Proskorovsky I, Lewis P, et al. Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study. Support Care Cancer 2014;22(2):417-26
   PubMed Web of Science ®Google Scholar
• Sloot S, Boland J, Snowden J, et al. Side effects of analgesia may significantly reduce quality of life in symptomatic multiple myeloma: a cross-sectional prevalence study. Support Care Cancer 2015;23:671-8
   Google Scholar
• Terpos E, Berenson J, Raje N, et al. Management of bone disease in multiple myeloma. Expert Rev Hematol 2014;7:113-25
   PubMed Web of Science ®Google Scholar
• Rood JA, van Zuuren F, Stam F, et al. Perceived need for information among patients with a haematological malignancy: associations with information satisfaction and treatment decision-making preferences. Hematol Oncol 2014. [Epub ahead of print]
   Google Scholar
• Palumbo A, Mateos MV, Bringhen S, et al. Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients? Blood Rev 2011;25:181-91
   PubMed Web of Science ®Google Scholar
• Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007. National Cancer Institute, Bethesda, MD. Available from: http://seer.cancer.gov/csr/1975_2007/; based on November 2009 SEER data submission, posted to the SEER Web site 2010
   Google Scholar
• Schaapveld M, Visser O, Siesling S. Improved survival among younger patients but not among older patients with multiple myeloma in the Netherlands, a population-based study since 1989. Eur J Cancer 2010;46:160-9
   PubMed Web of Science ®Google Scholar
• Ludwig H, Durie BG, Bolejack V, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10549 patients from the International Myeloma Working Group. Blood 2008;111(8):4039-47
   PubMed Web of Science ®Google Scholar
• Fried LP, Ferrucci L, Dauer J, et al. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 2004;59(3):255-63
   PubMed Web of Science ®Google Scholar
• Bringhen S, Mateos M, Zweegman S, et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica 2013;98(6):980-8
   PubMed Web of Science ®Google Scholar
• Cherubini A, Pierri F, Gasperini B, et al. Are ongoing trials on hematologic malignancies still excluding older subjects? Haematologica 2013;98(7):997-1000
   Google Scholar
• Takamatsu H, Honda S, Miyamoto T, et al. Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era. Cancer Sci 2014. [Epub ahead of print]
   Google Scholar
• Offidani M, Corvatta L, Polloni C, et al. Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma Registry. Clin Lymphoma Myeloma Leuk 2012;12(6):423-32
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma: an International Myeloma Working Group report. Blood 2015. [Epub ahead of print]
   Google Scholar
• Kleber M, Ihorst G, GroB B, et al. Validation of the Freiburg Comorbidity Index in 466 Multiple Myeloma patients and combination with the International Staging System are highly predictive for outcome. Clin Lymphoma Myeloma Leuk 2013;13(5):541-51
   PubMed Web of Science ®Google Scholar
• Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 2014;32(24):2595-603
   PubMed Web of Science ®Google Scholar
• Kenis C, Bron D, Libert Y, et al. Relevance of a systemic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study. Ann Oncol 2013;24(5):1306-12
   PubMed Web of Science ®Google Scholar
• Palumbo A, Waage A, Hulin C, et al. Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica 2013;98:87-94
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-17
   PubMed Web of Science ®Google Scholar
• Hulin C, Facon T, Shustik C, et al. Effect of Age on efficacy and safety outcomes in patients with Newly Diagnosed Multiple Myeloma (NDMM) receiving Lenalidomide and Low-Dose Dexamethasone (Rd): the FIRST trial. 56th ASH Annual Meeting Abstracts, San Francisco; 2014; 653:81
   Google Scholar
• Benboubker L, Dimopoulos M, Dispenzieri A, et al. Lenalidomide and dexamethasonein transplant-ineligible patients with myeloma. N Eng J Med 2014;371(10):906-17
   PubMed Web of Science ®Google Scholar
• Kent E, Ambs A, Mitchell S, et al. Health-related quality of life in older adult survivors of selected cancers: data from the SEER-MHOS Linkage. Cancer 2014. [Epub ahead of print]
   Google Scholar
• Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011;12(5):431-40
   PubMed Web of Science ®Google Scholar
• Hamaker ME, Prins MC, Stauder R. The relevance of a geriatric assessment for elderly patients with a hematological malignancy. A systematic review. Leuk Res 2014;38:275-83
   PubMed Web of Science ®Google Scholar
• Chng WJ, Dispenzieri A, Chin CS, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia 2014;28:269-77
   PubMed Web of Science ®Google Scholar